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Abstract
Breast cancer metastasis is a leading cause of death by malignancy in women worldwide. Efforts are being made to further
characterize the rate-limiting steps of cancer metastasis, i.e. extravasation of circulating tumor cells and colonization of
secondary organs. In this study, we investigated whether angiotensin II, a major vasoactive peptide both produced locally
and released in the bloodstream, may trigger activating signals that contribute to cancer cell extravasation and metastasis.
We used an experimental in vivo model of cancer metastasis in which bioluminescent breast tumor cells (D3H2LN) were
injected intra-cardiacally into nude mice in order to recapitulate the late and essential steps of metastatic dissemination.
Real-time intravital imaging studies revealed that angiotensin II accelerates the formation of metastatic foci at secondary
sites. Pre-treatment of cancer cells with the peptide increases the number of mice with metastases, as well as the number
and size of metastases per mouse. In vitro, angiotensin II contributes to each sequential step of cancer metastasis by
promoting cancer cell adhesion to endothelial cells, trans-endothelial migration and tumor cell migration across
extracellular matrix. At the molecular level, a total of 102 genes differentially expressed following angiotensin II pre-
treatment were identified by comparative DNA microarray. Angiotensin II regulates two groups of connected genes related
to its precursor angiotensinogen. Among those, up-regulated MMP2/MMP9 and ICAM1 stand at the crossroad of a network
of genes involved in cell adhesion, migration and invasion. Our data suggest that targeting angiotensin II production or
action may represent a valuable therapeutic option to prevent metastatic progression of invasive breast tumors.
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Introduction
The occurrence of distant metastasis is a critical event that limits
the survival of patients with breast cancer. While targeted
molecular therapies have considerably improved the management
of primary breast tumors, these remain poorly effective for the
treatment of distant metastases. The identification of molecular
agents that may contribute to breast cancer cell dissemination is
therefore essential for future development of new anti-metastatic
therapeutic strategies.
Metastasis is an inefficient process. Among the large number of
cancer cells that detach from the primary tumor and invade
adjacent tissues to reach the bloodstream, most remain quiescent
or die in the circulation [1–3]. Only few circulating tumor cells are
able to cross the blood barrier and colonize distant organs to form
micrometastases [3–5]. There is increasing evidence that, in
addition to intrinsic metastasis gene signatures that predict the
ability of tumor cells to colonize distant tissues [6], close
interactions between circulating tumor cells and the host
microenvironment are critical to the establishment of cancer cells
at secondary sites [7–9]. Diffusible molecules such as cytokines or
chemokines (CXCL12, CCL2) play a seminal role in breast cancer
metastasis [10,11]. We reasoned that other small molecules such as
vasoactive peptides, either produced locally or released in the
blood flow, may trigger activating signals contributing in an
autocrine or paracrine manner to cancer cell extravasation,
colonization and metastasis.
Angiotensin II (AngII) is the biologically active peptide of the
renin-angiotensin system (RAS) involved in blood pressure control,
tissue remodeling and angiogenesis as well as in vascular and
inflammatory pathologies. Of interest, major functions attributed
to AngII (inflammation, angiogenesis and migration) are also
related to cancer progression [12,13]. Most components of the
RAS including angiotensinogen, angiotensin converting enzyme
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variety of tumors, including in breast tumors [13–15]. Local
production of AngII in gastric cancer has been shown to facilitate
tumor progression and lymph node metastasis [16,17]. Further-
more, blockers of the RAS (either ACE inhibitors or angiotensin
receptor blockers ARBs) were shown to efficiently reduce tumor
growth, angiogenesis and metastasis in mouse experimental
models in vivo [12,13,18,19]. However, anti-metastatic properties
of RAS inhibitors were mainly associated with effects on the host
microenvironment, including infiltration of tumor-associated
macrophages or tumor-related angiogenesis [20,21], and to date
there has been no report on potential metastatic effects of AngII
through direct cancer cell activation.
In this study, we aimed to investigate whether AngII may act
directly on tumor cells to modify their metastatic properties. We
demonstrate that pre-treatment of breast cancer cells by AngII
triggers rapid development of metastatic foci at secondary sites in
an experimental mouse model in vivo and potentiates cancer cell
motility and transendothelial migration.
Results
Angiotensin II accelerates the development of
metastases in vivo
An experimental mouse model of cancer metastasis was
developed to investigate the effects of AngII on the metastatic
potential of breast cancer cells in vivo. Highly metastatic human
breast cancer cells D3H2LN (an in vivo-selected subclone of MDA-
MB-231 cells expressing luciferase [22]) were exposed to AngII
(100 nM) for 24 hrs (or vehicle for control group) and injected
intra-cardiacally into the bloodstream of nude mice in order to
recapitulate the late and essential steps of cancer metastasis, i.e.
extravasation and colonization [22,23]. Such strategy allowed us
to evaluate the effects of AngII on cancer cells while avoiding any
direct effect of the peptide on the host microenvironment.
The establishment of tumor micrometastases in various organs
was evaluated every two days by intravital bioluminescent imaging
on anesthetized animals. Fourteen mice injected with AngII-
treated cells were compared to 15 control mice, in two
independent experiments. As shown in Fig. 1A, mice from both
groups showed detectable micrometastases as early as day 7 post-
injection and all of them harbored metastases at day 19,
illustrating high aggressiveness of the D3H2LN cell line. However,
tumor cells exposed to AngII acquired a more aggressive behavior,
showing at least one metastatic site in 50% (7/14) of the animals at
day 7 as compared to 26,7% (4/15) of control mice. At day 9 of
the experiment, 86% (12/14) of the mice that received AngII-
treated cells presented at least one detectable metastatic nodule,
compared to 40% (6/15) for control mice (Fig. 1A). Notably,
AngII pre-treatment not only increased the percentage of mice
with metastasis, but also increased the number of detectable
metastatic foci per mouse (Fig. 1B) as well as the total number of
tumor cells disseminated in the whole body, as assessed by
quantification of bioluminescence (Fig. 1C). Ex-vivo analysis of
bioluminescence in isolated organs (not shown) and subsequent
histological analysis (Fig. 1D) on the last day of the experiment
confirmed the presence of tumor cells in the brain, lung and bone
samples that had been identified as luciferase-positive in the whole
animal.
The most significant differences between AngII-pretreated and
control groups were observed shortly after cell injection, as
illustrated by pictures of 5 representative mice taken at (Fig. 1E).
Indeed, breast cancer cells treated with AngII developed three
times more metastatic foci per mouse at day 9 compared to
control cells (Fig. 1B, Fig. S1A). In agreement, the number of
disseminated cancer cells was significantly increased in the AngII-
treated group as compared to control (median 1.155 and
0.525610
6 of photons/s respectively, at day 9 post-injection)
(Fig. 1C, Fig. S1B). Our results thus indicate that invasive
D3H2LN breast cancer cells exposed to AngII show increased
metastatic potential in vivo and are more prone to rapidly establish
at distant organs.
Angiotensin II increases breast cancer cell adhesion and
migration
Metastatic dissemination of circulating cancer cells involves
several sequential steps, among which tumor cell adhesion to the
vascular endothelium, migration across the endothelial barrier and
subsequent invasion across the extracellular matrix to reach a
secondary site. In order to evaluate the consequences of AngII
activation on cancer cell adhesion and migration, the properties of
MDA-MB-231 and D3H2LN breast cancer cells were analyzed in
vitro following pre-treatment with AngII. As shown in Fig. 2A,
AngII stimulation for 24 hrs significantly increased (1.7 fold) the
adhesion of cancer cells to a monolayer of human endothelial cells.
Cancer cell adhesion following AngII stimulation was also
increased (2 fold) when endothelial cells were pre-activated for
24 hrs with pro-inflammatory cytokines (IFNc and TNFa). To
note, short-term exposure (30 min or 6 hrs) of breast cancer cells
to AngII was not sufficient to promote increased adhesion to the
endothelial monolayer (data not shown), suggesting that AngII-
increased cancer cell adhesion may involve transcriptional
regulation of target genes rather than activation of intracellular
trafficking or signaling pathways – that generally occur within
minutes.
We next evaluated the effects of AngII on breast cancer cell
migration. As shown in Fig. 2B, pre-treatment of breast cancer
cells with AngII for 24 hrs significantly increased (1.5 fold) their
ability to migrate in Boyden chamber assays using FCS as
chemoattractant. Similar results were obtained in invasion assays
using filters coated with matrigelH that mimics the extracellular
matrix (Fig. 2C). The pro-migratory effects of AngII on breast
cancer cells were further confirmed in wound healing assays
(Fig. 2D, E) showing significant increase (1.64 fold) in cell
migration and wound closure at 16 hrs following pre-treatment
with AngII. To note, AngII-pre-treatment had no significant effect
on cell proliferation (Fig. S2), ruling out the possibility that
increased cell number may account for increased wound closure.
Finally, exposure of breast cancer cells to AngII induced a 2.7 fold-
increase in trans-endothelial migration, i.e. the ability to migrate
through a monolayer of human endothelial cells (Fig. 2F), which is
a hallmark of cancer cell extravasation in vitro.
Thus, AngII contributes to each step of breast cancer cell
extravasation including tumor cell adhesion to endothelial cells,
motility, invasion and trans-endothelial migration.
Angiotensin II regulates a panel of connected target
genes
To get further insight into the mechanisms by which AngII
increases breast cancer cell migration and metastasis, we searched
for downstream molecular targets that may be regulated following
exposure of MDA-MB-231 cells to AngII for 24 hrs. Comparative
DNA microarray (Affymetrix U133A) studies revealed a panel of
123 differentially expressed genes (more than 1.4-fold, p,0.05).
Among those, 102 genes (63 up-regulated and 39 down-regulated)
were associated with known functions (Tables S1 and S2)
including cell proliferation and apoptosis (32%), cell adhesion
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Accordingly, these genes were found to contribute to intracellular
protein kinase pathways (21%) or small GTPase signaling (17%)
(Table S4). Of interest, a large number of differentially regulated
genes (25%) were also related to cell metabolism, a finding that
opens new areas of investigation regarding the effects of AngII in
cancer cells.
Except for one up-regulated gene (encoding anti-apoptotic
molecule ATAD3A), differential regulation by AngII at 24 hrs did
not exceed a factor of 3 (Table S1), suggesting that AngII may
induce fine-tuned modulation of a wide number of genes involved
in various signaling pathways, rather than strong activation or
inhibition of a restricted set of specific genes. Ingenuity Pathway
Analysis (IPA) software revealed a network of genes centered
around angiotensinogen (AGT), the precursor of AngII (Fig. 3A).
Remarkably, two main groups of regulated genes could be
distinguished, one being related to MAP kinase (MAPK1) a major
effector of cell proliferation and inflammation (comprising
MAPK1, MAP2K7, MKNK2, PAWR, ARHGEF12, IGF1R,
RASGRF1 and DOK1), the other one being connected to matrix
metalloproteases MMP2 and MMP9 (also comprising ICAM1,
ITGB2, BSG, CDKN1, ANAPC10, SMAD2, RASGRF1 and
DOK1), well-known mediators of cell invasion and matrix
remodeling (Fig. 3A). Notably, RASGFR1 and DOK1 belong to
both groups of connected genes.
To note, microarray studies indeed revealed an increase in
MMP2 and MMP9 expression levels in response to AngII
stimulation, although results did not reach significance due to
heterogeneity of probesets hybridization. The pivotal position of
these genes within the network of AngII-regulated targets
prompted us to further investigate their differential expression by
RT-PCR. As shown in Fig. 3B and 3C, AngII dose-dependently
increases the mRNA levels of MMP2 (2-fold) and MMP9 (3-fold)
but not MMP3 nor MMP1 (not shown). Lipopolysaccharide (LPS),
as well-known potent inducer of MMPs expression and activity,
was used as a positive control for AngII efficiency. Dose-dependent
activation of MMP9 enzymatic (gelatinase) activity, reaching a 2-
fold increase at 100 nM AngII, was further confirmed by
zymography analysis (Fig. 3D). Of interest, Intercellular Adhesion
Molecule (ICAM-1), a major player in cell-cell adhesion and trans-
endothelial migration, also stands at the crossroad between AGT,
MMPs and integrins (Fig. 3A). In agreement with gene array
studies showing up-regulation of ICAM-1 mRNA (1.48 fold) by
AngII (Table S1), FACS analyses (Fig. 3E) further confirmed up-
regulation (1.8-fold) of ICAM-1 protein levels at the plasma
Figure 1. AngII increases the time-course, incidence and number of metastases in an experimental model in vivo. (A). Percentage of
mice showing at least one detectable metastasis over time after intracardiac injection of D3H2LN cells treated with AngII (red dotted line, n=14) or
vehicle (black line, n=15). (B). Number of metastases per mouse at indicated days. Results are mean +/2 SEM of 15 control (white bar) and 14 AngII-
treated (black bar) groups. (C). Number of photons/s per mouse at indicated days. Results are expressed as in B. (D). Histological analysis of
metastases developing at the brain (left panel), the lung (middle panel) and the bone (right panel), obtained from 3 mm sections of formalin-fixed,
paraffin-embedded tissue blocks stained with hematoxylin/eosin. Arrows indicate tumor cells. Magnification, 200x. (E). Representative pictures of 5
mice taken at day 9 after injection of control cells (upper panel) or AngII-treated cells (lower panel). * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0035667.g001
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Discussion
Pro-metastatic effects of AngII in various experimental models
in vivo have been attributed to its actions on the host
microenvironment [12,13,20,21]. We show here for the first time
that direct exposure of breast cancer cells to AngII contributes to
increased tumor-endothelial cell adhesion, trans-endothelial mi-
gration and motility, and accelerates metastatic progression in an
experimental mouse model in vivo. AngII is a potent vasoactive
peptide that can be both released in the bloodstream and
generated locally by endothelial, stromal and/or cancer cells.
We propose that autocrine or paracrine effects of AngII, either
present in the circulation or in the microenvironment of secondary
tissue, may trigger an activating signal facilitating the dissemina-
tion and establishment of micrometastases in target organs.
Cancer cell extravasation and metastatic colonization are rate-
limiting steps that involve reciprocal interactions between tumor
cells and the host stroma [24]. Extravasation requires cancer-
endothelial cell adhesion and subsequent trans-endothelial migra-
tion. Colonization in turn necessitates remodeling of the
extracellular matrix to invade and adapt to the new microenvi-
ronment [25], as well as activation of pro-survival pathways that
allow maintenance of cancer cells and their growth as microme-
tastases [24,26]. Data presented here provide evidence that AngII
transcriptionally modulates a wide range of coordinated genes that
contribute to cell adhesion/migration and proliferation/survival
through connection to matrix metalloprotease and MAP kinase
pathways, respectively. These observations are in support of the
functional studies reported here and suggest that AngII may
contribute to both extravasation and colonization of metastatic
breast cancer cells.
At the molecular level, previous studies have extensively
documented AngII-mediated regulation of MAP kinase pathways
in various cell types, in relation with mitogenic and anti-apoptotic
effects of the peptide [27]. We show here that AngII up-regulates
MMP2 and MMP9 gene expression and enzymatic activity in
breast cancer cells, in agreement with studies conducted in the
gastric cancer cell line MNK-28 [28]. Notably, we also report here
that AngII up-regulates the expression of Intercellular Adhesion
Molecule ICAM-1 at the mRNA and protein level. ICAM-1 is
well-known to trigger leukocyte adhesion to the endothelium and
Figure 2. AngII increases breast cancer cell adhesion and migration. (A). MDA-MB-231 breast cancer cell adhesion to HCMEC/D3 endothelial
cells monolayer following exposure of cancer cells to AngII (100 nM) for 24 hrs. Results are means +/2 SEM of 7 independent experiments performed
in quadruplicate, and expressed as fold increase of untreated cells (control, Ctrl). *p,0.05. (B, C). Boyden chamber assays of tumor cell migration
across 8 mm-pore filters either non coated (B) or coated with matrigel to mimic cell invasion (C). Results are means +/2 SEM of 3 separate
experiments performed in triplicate, and expressed as fold increase of control. *p,0.05. (D, E). Wound healing assay. Results are from 2 independent
experiments performed in quintuplicate, and expressed as fold increase of wound closure at time 16 hrs (T16) compared to control (vehicle-treated
cells). *p,0.05. (E). Representative pictures of wounds from control and AngII-treated cells (100 nM, 24 hrs) at T0 and T16. Magnification, 100x. (F).
Trans-endothelial migration. Results are mean +/2 SEM of 3 independent experiments performed in triplicate, and expressed as fold increase of
control. *p,0.05.
doi:10.1371/journal.pone.0035667.g002
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been shown to be increased by AngII in inflammatory situations
[29]. Our results show for the first time that ICAM-1 is up-
regulated in breast tumor cells in response to AngII treatment.
Relevance of this finding to human disease is supported by a
recent report showing that increased levels of ICAM-1 in breast
tumors are associated with a more aggressive phenotype [30], and
by studies highlighting the importance of vascular cell adhesion
molecules in the establishment of breast cancer cells at the
secondary site [31]. Other genes encoding adhesion molecules
Figure 3. AngII transcriptionally regulates a panel of connected genes. (A). Gene networks differentially regulated by AngII. Up- and down-
regulated genes related to angiotensinogen (AGT) are indicated in red and green, respectively. Filled lines indicate direct interactions, filled and
dashed arrows indicate direct and indirect regulations, respectively. Note two groups of connected genes centered around MAPK1 and MMP2/9,
respectively. (B). RT-PCR analysis of MMP9, MMP2 and MMP3 mRNA expression in MDA-MB-231 cells treated for 24 hrs with increasing doses of AngII
as indicated, or LPS (Lipopolysaccharide, 100 ng/ml) as a positive control. GAPDH amplification was used as internal control. Shown is one out of 3 to
5 independent experiments performed in duplicate. (C). Quantification (Image J software) of PCR amplification of MMP9, MMP2 and MMP3 relative to
GAPDH and normalized to expression levels in cells treated with 1 nM AngII. (D). Gelatin-based zymography analysis of MMP9 activity in conditioned
medium of cells treated as in B. Shown is one representative out of 3 independent experiments (Upper panel). Quantification (ImageJ software) of
results normalized to the quantity of proteins in cell lysate and expressed relative to control (lower panel). (E). FACS analysis of ICAM-1 expression at
the plasma membrane of MDA-MB-231 cells treated with AngII (100 nM) or vehicle for 24 hrs. Results are means +/2 SEM of 3 independent
experiments and expressed as fold-increase of the control. **p,0.01.
doi:10.1371/journal.pone.0035667.g003
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regulated by AngII (1.5 and 1.7 fold, respectively) (Table S1). Of
interest, FUT4 encodes fucosyltransferase which is involved in the
synthesis of sialyl-Lewis X, a well-known ligand of selectins
adhesion molecules, suggesting an indirect effect of AngII on the
selectin–selectin ligand axis.
We propose here a model in which direct stimulation of
circulating cancer cells by locally-produced AngII may regulate a
set of genes that ultimately influence the host microenvironment to
facilitate cancer cell extravasation, adaptation to the soil and
subsequent metastatic colonization. This model supports the
notion that targeting AngII production or action using ACE
inhibitors or ARBs, respectively, may represent an interesting
therapeutic option to prevent metastatic progression of invasive
breast tumors. In patients however, the question of whether RAS
blockers may have beneficial effects in cancer remains contradic-
tory [12,13,32–35], a finding that might reflect tumor heteroge-
neity in terms of RAS expression and local levels of AngII
production. Future prospective studies analyzing expression of
RAS components and AngII production in breast cancer may lead
to the identification of a subpopulation of tumors that respond to
ACE inhibitors and/or ARBs. Such agents being largely used in
the clinics as antihypertensive agents with mild side effects may
constitute a major breakthrough for personalized therapy of
metastatic breast tumors.
Materials and Methods
Cell lines
MDA-MB-231-Luc-D3H2LN luciferase-positive breast cancer
cells (referred here as D3H2LN) were obtained from Caliper Life
Science (Xenogen, MA, USA) and grown as described previously
[23]. These cells were derived from a spontaneous lymph node
metastasis of the MDA-MB-231 adenocarcinoma cell line
expressing luciferase, as described [22]. Metastatic MDA-MB-
231 breast tumor cells were obtained and grown as described
previously [36]. Human vascular endothelial HCMEC/D3 cells
were immortalized from brain microcapillaries and grown as
described [37].
Animal studies
Intracardiac experimental mouse model of metastasis in vivo was
conducted as described [22,23]. Briefly, female nude mice of 8–
0 weeks (Janvier, France) were anesthetized by intraperitoneal
injection of 120 mg/kg ketamine and 6 mg/kg xylazine. D3H2LN
cells expressing luciferase were pre-treated with 100 nM AngII
(Sigma, France) or vehicle in serum-free medium for 24 hrs prior
to injection (100.000 cells in 100 ml sterile PBS) into the left
ventricle of the heart by non surgical means. Anesthetized mice
were placed in the IVIS
TM Imaging System (Xenogen, Caliper
Life Science, MA, USA) and imaged from both dorsal and ventral
views five minutes after intraperitoneal injection of D-luciferin
(Caliper Life Science). A successful intracardiac injection was
indicated on day 0 by systemic bioluminescence distributed
throughout the animal. Only mice with evidence of successful
injection were included in the experiment. Assessment of
subsequent metastasis was monitored by imaging using the
IVIS
TM Imaging System (Caliper Life Science), every 3–4 days
for up to 24 days on mice anesthetized by exposure to 1–3%
isoflurane. Experiments were carried out with the approval of the
De ´partement d’Expe ´rimentation Animale, Institut d’He ´matologie,
Ho ˆpital St-Louis ethical committee, and were performed twice on
7 to 8 mice per group.
For ex-vivo analysis, organs highlighted by bioluminescence in
whole mice were removed surgically after sacrifice of the animals
and rapidly incubated with D-luciferin before imaging using the
IVIS system. For histological analyses, sections (3 mm) of
metastatic organs were cut from formalin-fixed, paraffin-embed-
ded tissue blocks, counterstained with hematoxylin-eosin and
examined under an inverted microscope.
Tumor cell adhesion to endothelial cells and trans-
endothelial migration
For endothelial cell adhesion assay, tumor cells were pre-treated
with AngII (100 nM) or vehicle in serum-free medium for 24 hrs
prior to labeling using green fluorescent cell tracker CMFDA
(Molecular Probes) as recommended by the manufacturer.
Fluorescent tumor cells (100.000/well of 96-well plates) were
added for 30 min at 37uC to a monolayer of human endothelial
cells (HCMEC/D3) either left untreated or pre-treated for 24 hrs
with pro-inflammatory cytokines IFNc (200 U/ml) and TNFa
(100 U/ml). After extensive washing, adherent cells were lysed in
water and tumor cells were quantified in a fluorescent microplate
reader at wavelength 485/530 nm. Experiments were performed
in quadruplicate.
For trans-endothelial migration assay, endothelial HCMEC/D3
cells (20.000/well) were plated on collagen type I-coated Transwell
filters (8 mm pore filter) and grown to confluence. Serum starved
MDA-MB-231 cells (100.000/well) were pre-treated for 24 hrs
with AngII (100 nM) or vehicle prior to labeling with CMFDA cell
tracker as described before. Fluorescent tumor cells were added to
the endothelial monolayer in the presence of chemokine CXCL12
(100 ng/ml) in the lower compartment. After 24 hrs, cells
remaining in the upper chamber were removed with a cotton
swab and tumor cells having migrated through the endothelial
monolayer to the lower face of the filter were lysed with water and
quantified in a fluorescent microplate reader at wavelength 485/
530 nm. Experiments were performed in triplicate.
Cell migration
For Boyden chamber assays of cell migration, MDA-MB-231
cells (200.000/well) were pre-treated for 24 hrs with AngII
(100 nM) or vehicle and were then seeded on the upper chamber
of 8 mm-Transwell filters (Corning, NY, USA) either coated or not
with 10 mg/ml matrigel (BD Biosciences), and allowed to migrate
for 18 hrs in the presence of 10% FCS in the lower compartment.
Cells migrating to the lower face of the filters were fixed in
methanol, stained with crystal violet and counted under an
inverted microscope. Experiments were performed in triplicate.
For wound healing assays, D3H2LN cells were pre-treated for
24 hrs with AngII (100 nM) or vehicle and were then grown to
confluence in 24-well plates before cross-shape wounds were
performed in the monolayer using a sterile 10 ml pipette tip.
Wounds were registered by phase contrast microscopy immedi-
ately after scratching (T0) and after 16 hrs in serum-free medium
(T16), and quantified using ImageJ software (http://rsb.info.nhi.
gov/ij/). For each condition the ratio of wound closure at T16
relative to T0 was calculated.
Gene array studies
Total RNA from MDA-MB-231 cells treated for 24 hrs with
AngII (100 nM) or vehicle, was extracted using Trizol (Invitrogen)
and analyzed with the Affymetrix Human Genome U133 Plus 2.0
Gene Chips (a genome wide array with 54674 probe sets targeting
19418 transcripts) as described [38]. Gene expression levels were
normalized using the GC-RMA algorithm and flags were
Pro-Metastatic Effects of AngII in Breast Cancer
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performed with affyQCReport R package (R project for Statistical
Computing [http://www.r-project.org/]). Each data set was
derived from triplicates of biologically independent samples and
compared using Student’s t test. To estimate the false discovery
rate the resulting p values were filtered at 5%. Microarray
experiments were performed according to the MIAME consor-
tium guidelines. Data have been submitted to MIAMEarray
express under accession number E-MEXP-3470 and the release
date is 2012-12-05. Data were submitted to Ingenuity Pathway
Analysis (IPA) to model relationships among genes and proteins
and to construct putative pathways and relevant biological
processes (http://www.ingenuity.com).
RT-PCR analysis
Total RNA was extracted from MDA-MB-231 cells treated as
indicated, and cDNA was reverse-transcribed using oligo-dT and
superscript RT (Invitrogen) as recommended by the manufacturer.
PCR amplification (35 cycles, annealing temperature 55uC) was
performed on 25 ng cDNA using oligonucleotide primers as
follows: MMP9-F 59AAG TAC TGG CGA TTC TCT GAG
GG; MMP9-R 59GGC TTT CTC TCG GTA CTG GAA GAC;
MMP2-F 59TTT TCT CGA ATC CAT GAT GG; MMP2-R
59CTG GTG CAG CTC TCA TAT TT; MMP3-F 59CCT
GCT TTG TCC TTT GAT GC; MMP3-R 59TGA GTC AAT
CCC TGG AAA GTC; GAPDH-F 59GGA GAA GGC TGG
GGC; GAPDH-R 59GAT GGC ATG GAC TGT GG.
FACS analysis
MDA-MB-231 cells were treated for 24 hrs with AngII
(100 nM) or vehicle and harvested in 1mM EDTA. Expression
levels of ICAM-1 at the cell membrane were evaluated by FACS
analysis using Cytomics TM FC500 (Beckman Coulter) after
labeling with anti-ICAM-1 antibodies (R&D system).
Gelatin zymography
For analysis of metalloprotease enzymatic activity, conditioned
medium of MDA-MB-231 cells treated for 24 hrs with increasing
concentrations of AngII, or lipopolysaccharide (LPS, 100 ng/ml)
as positive control, were collected and loaded on gelatin (1 mg/
ml)-containing SDS-PAGE run at 4uC (zymography gels) as
described [23]. MMP9 activity was visualised as a clear band at
90 kDa after coomassie blue coloration, and quantified using
ImageJ software.
Statistical analysis
Statistical analyses were conducted using JMP-7 software. Data
in bar graphs (mean +/2 SEM) were analyzed using Student’s t-
test. p,0.05 was considered statistically significant.
Supporting Information
Figure S1 (A). Quantification of the number of metastases per
mouse at day 9. Shown are pooled results from 2 independent
experiments, black squares and black triangles representing
control (n=15) and AngII-treated (n=14) mice, respectively.
(B). Quantification of the number of photons/s per mouse at
day 9. Results are expressed as in (A). * p,0.05, ***p,0.001.
(TIF)
Figure S2 MTT assay of D3H2LN cells proliferation
following 24 hrs- pre-treatment with AngII (100 nM) or
vehicle. Shown is one representative experiment out of 3
performed in quadruplicate.
(TIF)
Table S1 Shown are the 63 genes up-regulated by AngII
(100 nM, 24 hrs) by 1.4-fold or more (p,0.05). The genes
are listed in alphabetical order, together with their main
characteristics and known functions (description/ Gene pathway/
function column), differential regulation by AngII (fold column)
and p value. (a): Genes connected to Angiotensinogen pathway
AGT (as illustrated in Figure 3A) are indicated by an asterisk *.
(DOC)
Table S2 Shown are the 39 genes down-regulated by
AngII (100 nM, 24 hrs) by 1.4-fold or more (p,0.05). The
genes are listed in alphabetical order as indicated in Table S1. (a):
Genes connected to Angiotensinogen pathway AGT (as illustrated
in Figure 3A) are indicated by an asterisk *.
(DOC)
Table S3 Genes regulated by AngII are classified
according to their major functions namely Inflamma-
tion, Cell Proliferation and Apoptosis, Adhesion and
Migration, Metabolism. Genes with others functions appear
in the ‘‘others’’ section. Number of genes is indicated under
parenthesis. Up-regulated genes are indicated in bold whereas
down-regulated genes are indicated in standard font.
(DOC)
Table S4 Genes regulated by AngII are organized in
four major pathways related to protein kinase signaling,
small GTPases, Ubiquitin/proteasome and intracellular
traffic. Number of genes is indicated under parenthesis. Up-
regulated genes are indicated in bold whereas down-regulated
genes are indicated in standard font.
(DOC)
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